Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?

摘要
参考文献
相关文章
推荐阅读
Metrics

下载:

PDF (7361KB)
输出: BibTeX | EndNote (RIS)

摘要 Prostate cancers (PCa) have been reported to actively suppress antitumor immune responses by creating an immune-suppressive microenvironment. There is mounting evidence that PCas may undergo an "Epithelial Immune Cell-like Transition" (EIT) by expressing molecules conventionally associated with immune cells (e.g., a variety of cytokines/receptors, immune transcription factors, Ig motifs, and immune checkpoint molecules), which subsequently results in the suppression of anti-cancer immune activity within the tumor microenvironment. Recent progress within the field of immune therapy has underscored the importance of immune checkpoint molecules in cancer development, thus leading to the development of novel immunotherapeutic approaches. Here, we review the expression of select immune checkpoint molecules in PCa epithelial and associated immune cells, with particular emphasis on clinical data supporting the concept of an EIT-mediated phenotype in PCa. Furthermore, we summarize current advances in anti-immune checkpoint therapies, and provide perspectives on their potential applicability.

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	（）
	作者相关文章
	Dong Lin
	Xinya Wang
	Stephen Yiu Chuen Choi
	Xinpei Ci
	Xin Dong
	Yuzhuo Wang

关键词: Prostate cancer Immune checkpoint Epithelial immune cell-like transition Immune suppression Immune therapy

Abstract: Prostate cancers (PCa) have been reported to actively suppress antitumor immune responses by creating an immune-suppressive microenvironment. There is mounting evidence that PCas may undergo an "Epithelial Immune Cell-like Transition" (EIT) by expressing molecules conventionally associated with immune cells (e.g., a variety of cytokines/receptors, immune transcription factors, Ig motifs, and immune checkpoint molecules), which subsequently results in the suppression of anti-cancer immune activity within the tumor microenvironment. Recent progress within the field of immune therapy has underscored the importance of immune checkpoint molecules in cancer development, thus leading to the development of novel immunotherapeutic approaches. Here, we review the expression of select immune checkpoint molecules in PCa epithelial and associated immune cells, with particular emphasis on clinical data supporting the concept of an EIT-mediated phenotype in PCa. Furthermore, we summarize current advances in anti-immune checkpoint therapies, and provide perspectives on their potential applicability.

Key words: Prostate cancer Immune checkpoint Epithelial immune cell-like transition Immune suppression Immune therapy

收稿日期: 2016-06-25 修回日期: 2016-08-09 出版日期: 2016-10-01 发布日期: 2016-11-02 整期出版日期: 2016-10-01

通讯作者: Yuzhuo Wang,E-mail address: ywang@bccrc.ca E-mail: ywang@bccrc.ca

引用本文:

Dong Lin, Xinya Wang, Stephen Yiu Chuen Choi, Xinpei Ci, Xin Dong, Yuzhuo Wang. Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?[J]. Asian Journal of Urology, 2016, 3(4): 195-202.
Dong Lin, Xinya Wang, Stephen Yiu Chuen Choi, Xinpei Ci, Xin Dong, Yuzhuo Wang. Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?. Asian Journal of Urology, 2016, 3(4): 195-202.

链接本文:

http://www.ajurology.com/CN/ 或 http://www.ajurology.com/CN/Y2016/V3/I4/195

[1]	de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
[2]	Richard CC, Nancy Lee H, Eric SR, Jo-Anne OS, Alice MC, Sally HE, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
[3]	de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment:a randomised open-label trial. Lancet 2010;376:1147-54.
[4]	Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23.
[5]	Choi SY, Gout PW, Collins CC, Wang Y. Epithelial immune celllike transition (EIT):a proposed transdifferentiation process underlying immune-suppressive activity of epithelial cancers. Differentiation 2012;83:293-8.
[6]	Huen NY, Pang AL, Tucker JA, Lee TL, Vergati M, Jochems C, et al. Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castrationresistant prostate cancer. Int J Cancer 2013;133:373-82.
[7]	Miller AM, Lundberg K, Ozenci V, Banham AH, Hellstrom M, Egevad L, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177:7398-405.
[8]	Flammiger A, Weisbach L, Huland H, Tennstedt P, Simon R, Minner S, et al. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur J Cancer 2013;49:1273-9.
[9]	Idorn M, Kollgaard T, Kongsted P, Sengelov L, Thor Straten P. Correlation between frequencies of blood monocytic myeloidderived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother 2014; 63:1177-87.
[10]	Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, et al. Immunosuppressive CD14+HLA-DRlow/-monocytes in prostate cancer. Prostate 2010;70:443-55.
[11]	Lanciotti M, Masieri L, Raspollini MR, Minervini A, Mari A, Comito G, et al. The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy. Biomed Res Int 2014;2014:486798.
[12]	Nonomura N, Takayama H, Nakayama M, Nakai Y, Kawashima A, Mukai M, et al. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int 2011;107:1918-22.
[13]	Gannon PO, Poisson AO, Delvoye N, Lapointe R, MesMasson AM, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009;348:9-17.
[14]	Pasero C, Gravis G, Guerin M, Granjeaud S, Thomassin-Piana J, Rocchi P, et al. Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity. Cancer Res 2016;76:2153-65.
[15]	Lundholm M, Schroder M, Nagaeva O, Baranov V, Widmark A, Mincheva-Nilsson L, et al. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells:mechanism of immune evasion. PLoS One 2014; 9:e108925.
[16]	Garcia AJ, Ruscetti M, Arenzana TL, Tran LM, Bianci-Frias D, Sybert E, et al. Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol 2014;34:2017-28.
[17]	Xu J, Escamilla J, Mok S, David J, Priceman S, West B, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res 2013;73:2782-94.
[18]	Pu Y, Xu M, Liang Y, Yang K, Guo Y, Yang X, et al. Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse. Sci Transl Med 2016;8. 333ra47.
[19]	Tang S, Moore ML, Grayson JM, Dubey P. Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. Cancer Res 2012; 72:1975-85.
[20]	Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11:3887-95.
[21]	Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.
[22]	Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8:765-72.
[23]	Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses:the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 2013;14:1212-8.
[24]	Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56-61.
[25]	Sfanos KS, Bruno TC, Meeker AK, De Marzo AM, Isaacs WB, Drake CG. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 2009;69:1694-703.
[26]	Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-77.
[27]	Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis:a potentialmechanismofimmuneevasion.NatMed2002;8:793-800.
[28]	Zang X, Allison JP. The B7 family and cancer therapy:costimulation and coinhibition. Clin Cancer Res 2007;13:5271-9.
[29]	Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
[30]	Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064-74.
[31]	Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, et al. Paucity of PD-L1 expression in prostate cancer:innate and adaptive immune resistance. Prostate Cancer Prostatic Dis 2015;18:325-32.
[32]	Massari F, Ciccarese C, Calio A, Munari E, Cima L, Porcaro AB, et al. Magnitude of PD-1, PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma:an exploratory analysis. Target Oncol 2015;11:345-51.
[33]	Gevensleben H, Dietrich D, Golletz C, Steiner S, Jung M, Thiesler T, et al. The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. Clin Cancer Res 2016;22:1969-77.
[34]	Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 2013; 34:556-63.
[35]	Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. B7-H3:a costimulatory molecule for T cell activation and IFNgamma production. Nat Immunol 2001;2:269-74.
[36]	Katayama A, Takahara M, Kishibe K, Nagato T, Kunibe I, Katada A, et al. Expression of B7-H3 in hypopharyngeal squamous cell carcinoma as a predictive indicator for tumor metastasis and prognosis. Int J Oncol 2011;38:1219-26.
[37]	Gregosiewicz A, Wosko I, Kandzierski G, Drabik Z. Doubleelevating osteotomy of tibiae in the treatment of severe cases of Blount's disease. J Pediatr Orthop 1989;9:178-81.
[38]	Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 2007;104:19458-63.
[39]	Tekle C, Nygren MK, Chen YW, Dybsjord I, Nesland JM, Maelandsmo GM, et al. B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int J Cancer 2012;130:2282-90.
[40]	Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, et al. B7-H3 ligand expression by prostate cancer:a novel marker of prognosis and potential target for therapy. Cancer Res 2007;67:7893-900.
[41]	Yuan H, Wei X, Zhang G, Li C, Zhang X, Hou J. B7-H3 over expression in prostate cancer promotes tumor cell progression. J Urol 2011;186:1093-9.
[42]	Liu Y, Vlatkovic L, Saeter T, Servoll E, Waaler G, Nesland JM, et al. Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3- expressing cell population? Int J Urol 2012;19:749-56.
[43]	Parker AS, Heckman MG, Sheinin Y, Wu KJ, Hilton TW, Diehl NN, et al. Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys 2011; 79:1343-9.
[44]	Chavin G, Sheinin Y, Crispen PL, Boorjian SA, Roth TJ, Rangel L, et al. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res 2009;15:2174-80.
[45]	Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x:a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A 2003;100:10388-92.
[46]	Prasad DV, Richards S, Mai XM, Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 2003;18:863-73.
[47]	Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003;18:849-61.
[48]	Krambeck AE, Thompson RH, Dong H, Lohse CM, Park ES, Kuntz SM, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature:associations with cancer progression and survival. Proc Natl Acad Sci U S A 2006;103:10391-6.
[49]	Liu W, Shibata K, Koya Y, Kajiyama H, Senga T, Yamashita M, et al. B7-H4 overexpression correlates with a poor prognosis for cervical cancer patients. Mol Clin Oncol 2014;2:219-25.
[50]	Chen LJ, Sun J, Wu HY, Zhou SM, Tan Y, Tan M, et al. B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother 2011;60:1047-55.
[51]	Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, et al. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res 2008;68:6054-8.
[52]	Qian Y, Yao HP, Shen L, Cheng LF, Zhang LH. Expression of B7- H4 in prostate cancer and its clinical significance. Zhejiang Univ Med Sci 2010;39:345-9.
[53]	Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002;415:536-41.
[54]	Ngiow SF, Teng MW, Smyth MJ. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res 2011;71:6567-71.
[55]	Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol 2011;32:345-9.
[56]	Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007;318:1141-3.
[57]	Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, et al. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One 2012;7:e30676.
[58]	Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010;207:2175-86.
[59]	Wu J, Liu C, Qian S, Hou H. The expression of Tim-3 in peripheral blood of ovarian cancer. DNA Cell Biol 2013;32:648-53.
[60]	Piao YR, Jin ZH, Yuan KC, Jin XS. Analysis of Tim-3 as a therapeutic target in prostate cancer. Tumour Biol 2014;35:11409-14.
[61]	Piao YR, Piao LZ, Zhu LH, Jin ZH, Dong XZ. Prognostic value of T cell immunoglobulin mucin-3 in prostate cancer. Asian Pac J cancer Prev 2013;14:3897-901.
[62]	Norde WJ, Hobo W, van der Voort R, Dolstra H. Coinhibitory molecules in hematologic malignancies:targets for therapeutic intervention. Blood 2012;120:728-36.
[63]	Collins AV, Brodie DW, Gilbert RJ, Iaboni A, Manso-Sancho R, Walse B, et al. The interaction properties of costimulatory molecules revisited. Immunity 2002;17:201-10.
[64]	Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009;229:12-26.
[65]	Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993;11:191-212.
[66]	Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-13.
[67]	Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 2005;201:1257-68.
[68]	Powderly J, Cote G, Flaherty K, Szmulewitz RZ, Ribas A, Weber J, et al. Interim results of an ongoing Phase I, dose escalation study of MGA271(Fc-optimized humanized anti-B7- H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3. J Immunother Cancer 2015;3:O8.
[69]	Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
[70]	Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
[71]	Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007;13:1810-5.
[72]	O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 2007;13:958-64.
[73]	Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009;69:609-15.
[74]	Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer:results from an open-label, multicenter phase I/II study. Ann Oncol 2013;24:1813-21.

[1]	Per-Anders Abrahamsson. Intermittent androgen deprivation therapy in patients with prostate cancer:Connecting the dots[J]. Asian Journal of Urology, 2017, 4(4): 208-222.
[2]	Yoshiyasu Amiya, Yasutaka Yamada, Masahiro Sugiura, Makoto Sasaki, Takayuki Shima, Noriyuki Suzuki, Hiroomi Nakatsu, Shino Murakami, Jun Shimazaki. Outcomes of patients older than 75 years with non-metastatic prostate cancer[J]. Asian Journal of Urology, 2017, 4(2): 102-106.
[3]	Dingwei Ye, Yiran Huang, Fangjian Zhou, Keji Xie, Vsevolod Matveev, Changling Li, Boris Alexeev, Ye Tian, Mingxing Qiu, Hanzhong Li, Tie Zhou, Peter De Porre, Margaret Yu, Vahid Naini, Hongchuan Liang, Zhuli Wu, Yinghao Sun. A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapynaïve patients with mCRPC in China, Malaysia, Thailand and Russia[J]. Asian Journal of Urology, 2017, 4(2): 75-85.
[4]	Kai Zhang, Chris H. Bangma, Monique J. Roobol. Prostate cancer screening in Europe and Asia[J]. Asian Journal of Urology, 2017, 4(2): 86-95.
[5]	Geoffrey Gaunay, Vinay Patel, Paras Shah, Daniel Moreira, Simon J. Hall, Manish A. Vira, Michael Schwartz, Jessica Kreshover, Eran Ben-Levi, Robert Villani, Ardeshir Rastinehad, Lee Richstone. Role of multi-parametric MRI of the prostate for screening and staging: Experience with over 1500 cases[J]. Asian Journal of Urology, 2017, 4(1): 68-74.
[6]	Geoffrey S. Gaunay, Vinay Patel, Paras Shah, Daniel Moreira, Ardeshir R. Rastinehad, Eran Ben-Levi, Robert Villani, Manish A. Vira. Multi-parametric MRI of the prostate: Factors predicting extracapsular extension at the time of radical prostatectomy[J]. Asian Journal of Urology, 2017, 4(1): 31-36.
[7]	Matthew E. Pollard, Alan J. Moskowitz, Michael A. Diefenbach, Simon J. Hall. Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer[J]. Asian Journal of Urology, 2017, 4(1): 37-43.
[8]	Takeshi Hirata, Seung Chol Park, Michelle T. Muldong, Christina N. Wu, Tomonori Yamaguchi, Amy Strasner, Omer Raheem, Hiromi Kumon, Robert L. Sah, Nicholas A. Cacalano, Catriona H. M. Jamieson, Christopher J. Kane, Koichi Masuda, Anna A. Kulidjian, Christina A. M. Jamieson. Specific bone region localization of osteolytic versus osteoblastic lesions in a patient-derived xenograft model of bone metastatic prostate cancer[J]. Asian Journal of Urology, 2016, 3(4): 229-239.
[9]	Jin Xu, Yun Qiu. Role of androgen receptor splice variants in prostate cancer metastasis[J]. Asian Journal of Urology, 2016, 3(4): 177-184.
[10]	Jun Luo. Non-invasive actionable biomarkers for metastatic prostate cancer[J]. Asian Journal of Urology, 2016, 3(4): 170-176.
[11]	Eun-Jin Yun, U-Ging Lo, Jer-Tsong Hsieh. The evolving landscape of prostate cancer stem cell: Therapeutic implications and future challenges[J]. Asian Journal of Urology, 2016, 3(4): 203-210.
[12]	Belinda Nghiem, Xiaotun Zhang, Hung-Ming Lam, Lawrence D. True, Ilsa Coleman, Celestia S. Higano, Peter S. Nelson, Colin C. Pritchard, Colm Morrissey. Mismatch repair enzyme expression in primary and castrate resistant prostate cancer[J]. Asian Journal of Urology, 2016, 3(4): 223-228.
[13]	Shirley Cheng, Jie-Fu Chen, Yi-Tsung Lu, Leland W. K. Chung, Hsian-Rong Tseng, Edwin M. Posadas. Applications of circulating tumor cells for prostate cancer[J]. Asian Journal of Urology, 2016, 3(4): 254-259.
[14]	Zhiying Shao, Andrew Z. Wang, Daniel J. George, Tian Zhang. Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma[J]. Asian Journal of Urology, 2016, 3(4): 268-277.
[15]	Cameron M. Armstrong, Allen C. Gao. Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer[J]. Asian Journal of Urology, 2016, 3(4): 185-194.

[1]	Zhixiang Wang, Bing Liu, Xiaofeng Gao, Yi Bao, Yang Wang, Huamao Ye, Yinghao Sun, Linhui Wang. Laparoscopic ureterolysis with simultaneous ureteroscopy and percutaneous nephroscopy for treating complex ureteral obstruction after failed endoscopic intervention: A technical report[J]. Asian Journal of Urology, 2015, 2(4): 238 -243 .
[2]	Louis R. Kavoussi. News from leading international academic urology departments[J]. Asian Journal of Urology, 2017, 4(1): 1 -2 .
[3]	Rikiya Taoka, Yoshiyuki Kakehi. The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia[J]. Asian Journal of Urology, 2017, 4(3): 158 -163 .
[4]	Cheuk Fan Shum, Weida Lau, Chang Peng Colin Teo. Medical therapy for clinical benign prostatic hyperplasia:a1 Antagonists, 5a reductase inhibitors and their combination[J]. Asian Journal of Urology, 2017, 4(3): 185 -190 .
[5]	Foo Keong Tatt. Current consensus and controversies on male LUTS/BPH (part two)[J]. Asian Journal of Urology, 2018, 5(1): 8 -9 .
[6]	Rishi R. Sekar, Claire M. De La Calle, Dattatraya Patil, Sarah A. Holzman, Yoram Baum, Umer Sheikh, Jonathan H. Huang, Adeboye O. Osunkoya, Brian P. Pollack, Haydn T. Kissick, Kenneth Ogan, Viraj A. Master. Major histocompatibility complex I upregulation in clear cell renal cell carcinoma is associated with increased survival[J]. Asian Journal of Urology, 2016, 3(2): 75 -81 .
[7]	Ryan Yu, Jefferson Terry, Mutaz Alnassar, Jorge Demaria. Pediatric fibrous pseudotumor of the tunica vaginalis testis[J]. Asian Journal of Urology, 2016, 3(2): 99 -102 .
[8]	Aso Omer Rashid, Saman Salih Fakhulddin. Risk factors for fever and sepsis after percutaneous nephrolithotomy[J]. Asian Journal of Urology, 2016, 3(2): 82 -87 .
[9]	Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26 -32 .
[10]	Aldamanhori Reem,I.Osman Nadir,R.Chapple Christopher. Underactive bladder: Pathophysiology and clinical significance[J]. Asian Journal of Urology, 2018, 5(1): 17 -21 .

Viewed

Full text

Abstract

Cited

Shared

Discussed